Company: PRME
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023486
Chunk: 27

Company: Prime Medicine, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 27
---
 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Common StockAdditionalPaid-inCapitalAccumulated OtherComprehensiveLossesAccumulatedDeficitTotalStockholders’Equity(in thousands, except share amounts)SharesAmountBalance as of December 31, 202397,377,121 $2 $624,414 $(15)$(491,330)$133,071 Issuance of common stock from public offering, net of issuance costs of $8.9 million22,560,001 — 132,055 — — 132,055 Issuance of pre-funded warrants, net of issuance costs of $1.2 million— — 18,800 — — 18,800 Issuances of common stock under the employee stock purchase plan74,488 — 436 — — 436 Issuance of common stock upon exercise of stock options9,664 — 36 — — 36 Stock-based compensation expense— — 5,209 — — 5,209 Change in unrealized loss on investments, net of tax— — — (80)— (80)Net loss— — — — (45,761)(45,761)Balance as of March 31, 2024120,021,274 2 780,950 (95)(537,091)243,766 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

8

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three Months EndedMarch 31,(in thousands)20252024Cash flows used in operating activities:Net loss$(51,890)$(45,761)Adjustments to reconcile net loss to net cash used in operating activitiesStock-based compensation expense5,681 5,209 Non cash lease expense2,413 3,348 Depreciation expense1,700 1,315 Change in fair value of short-term investment — related party1,056 (1,166)Amortization of premiums and discount on short-term investments(164)(675)Deferred income taxes— 134